Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
| العنوان: | Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease |
|---|---|
| المؤلفون: | Sami Qadri, Noora Ahlholm, Ida Lønsmann, Paola Pellegrini, Anni Poikola, Panu K Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K Penttilä, Roberta D’Ambrosio, Giorgio Soardo, Diana J Leeming, Morten Karsdal, Johanna Arola, Stergios Kechagias, Serena Pelusi, Mattias Ekstedt, Luca Valenti, Hannes Hagström, Hannele Yki-Järvinen |
| المساهمون: | Department of Medicine, Clinicum, HUS Internal Medicine and Rehabilitation, Helsinki University Hospital Area, HUS Abdominal Center, Department of Surgery, HUSLAB, Department of Pathology |
| المصدر: | The Journal of Clinical Endocrinology & Metabolism. 107:e2008-e2020 |
| بيانات النشر: | The Endocrine Society, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Liver Cirrhosis, nonalcoholic fatty liver disease, obesity, Biopsy, ei-alkoholiperäinen rasvamaksatauti, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Gastroenterology and Hepatology, nonalcoholic steatohepatitis, fibrosis, cirrhosis, biomarkers, Biochemistry, BMI, Endocrinology, Non-alcoholic Fatty Liver Disease, NAFLD, rasvamaksatauti, Gastroenterologi, Humans, Aspartate Aminotransferases, painoindeksi, kirroosi, fibroosi, Biochemistry (medical), rasvamaksa, maksabiopsia, NASH, Cross-Sectional Studies, Liver, maksafibroosi, biomarkkeri, 3121 General medicine, internal medicine and other clinical medicine, ei-alkoholiperäinen steatohepatiitti, lihavuus |
| الوصف: | Context Guidelines recommend blood-based fibrosis biomarkers to identify advanced nonalcoholic fatty liver disease (NAFLD), which is particularly prevalent in patients with obesity. Objective To study whether the degree of obesity affects the performance of liver fibrosis biomarkers in NAFLD. Design Cross-sectional cohort study comparing simple fibrosis scores [Fibrosis-4 Index (FIB-4); NAFLD Fibrosis Score (NFS); aspartate aminotransferase to platelet ratio index; BARD (body mass index, aspartate-to-alanine aminotransferase ratio, diabetes); Hepamet Fibrosis Score (HFS)] and newer scores incorporating neo-epitope biomarkers PRO-C3 (ADAPT, FIBC3) or cytokeratin 18 (MACK-3). Setting Tertiary referral center. Patients We recruited overweight/obese patients from endocrinology (n = 307) and hepatology (n = 71) clinics undergoing a liver biopsy [median body mass index (BMI) 40.3 (interquartile range 36.0-44.7) kg/m2]. Additionally, we studied 859 less obese patients with biopsy-proven NAFLD to derive BMI-adjusted cutoffs for NFS. Main Outcome Measures Biomarker area under the receiver operating characteristic (AUROC), sensitivity, specificity, and predictive values to identify histological stage ≥F3 fibrosis or nonalcoholic steatohepatitis with ≥F2 fibrosis [fibrotic nonalcoholic steatohepatitis (NASH)]. Results The scores with an AUROC ≥0.85 to identify ≥F3 fibrosis were ADAPT, FIB-4, FIBC3, and HFS. For fibrotic NASH, the best predictors were MACK-3 and ADAPT. The specificities of NFS, BARD, and FIBC3 deteriorated as a function of BMI. We derived and validated new cutoffs for NFS to rule in/out ≥F3 fibrosis in groups with BMIs Conclusions In obese patients, the best-performing fibrosis biomarkers are ADAPT and the inexpensive FIB-4, which are unaffected by BMI. The widely used NFS loses specificity in obese individuals, which may be corrected with BMI-adjusted cutoffs. |
| وصف الملف: | application/pdf |
| تدمد: | 1945-7197 0021-972X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04738b7aebc1de640e4d88e4544005a6 https://doi.org/10.1210/clinem/dgab933 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....04738b7aebc1de640e4d88e4544005a6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19457197 0021972X |
|---|